A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 9, 2008, Pages 1415-1418

  Chen, Shaohua ^b   Li, Youming ^a,b   Li, Shengjie ^b   Yu, Chaohui ^b  

^a Zhejiang University College of Medicine First Affiliated Hospital ^*  (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Clinical hepatology; Metabolism hepatology; NAFLD; Pathogenesis hepatology

Indexed keywords

ALANINE; ALANINE AMINOTRANSFERASE; ALBUMIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; VALINE;

ABDOMINAL FAT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 49849093922     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05523.x     Document Type: Article

References (13)

1. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 2000 448 : 121 38.
2. Chen SH, Li YM, Yu CH, Jiang LL. The association of Val 227 Ala polymorphism of the peroxisome proliferator activated receptor alpha (PPAR alpha) gene with non-alcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 2007 15 : 64 5. Chinese.
3. Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases. Chin. J. Heptol. 2006 14 : 161 3.
4. Mishra P, Younossi ZM. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). Curr. Drug Discov. Technol. 2007 4 : 133 40.
5. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med. Clin. North Am. 2007 91 : 1125 49.
6. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 2004 15 : 2801 15.
7. van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res. 2004 21 : 1531 8.
8. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 2001 21 : 27 41.
9. Sparsø T, Hussain MS, Andersen G et al. Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol. Genet. Metab. 2007 90 : 205 9.
10. Yamakawa-Kobayashi K, Ishiguro H, Arinami T, Miyazaki R, Hamaguchi H. A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels. J. Med. Genet. 2002 39 : 189 91.
11. Naito H, Yamanoshita O, Kamijima M et al. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet Genomics 2006 16 : 569 77.
12. Naito H, Kamijima M, Yamanoshita O et al. Differential effects of aging, drinking and exercise on serum cholesterol levels dependent on the PPARA-V227A polymorphism. J. Occup. Health 2007 49 : 353 62.
13. Seedorf U, Assmann G. The role of PPAR alpha in obesity. Nutr. Metab. Cardiovasc. Dis. 2001 11 : 189 94.